Kazuma Ohyashiki
Overview
Explore the profile of Kazuma Ohyashiki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
297
Citations
3554
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Okuda R, Ochi Y, Saiki R, Yamanaka T, Terao C, Yoshizato T, et al.
Leukemia
. 2024 Dec;
39(3):760-764.
PMID: 39715854
No abstract available.
2.
Bernard E, Tuechler H, Greenberg P, Hasserjian R, Arango Ossa J, Nannya Y, et al.
NEJM Evid
. 2024 Feb;
1(7):EVIDoa2200008.
PMID: 38319256
BACKGROUND: Risk stratification and therapeutic decision-making for myelodysplastic syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS-R), which considers hematologic parameters and cytogenetic abnormalities. Somatic gene mutations are...
3.
Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, et al.
Cancer Sci
. 2023 May;
114(8):3461-3465.
PMID: 37232264
Progression-free survival after R-High CHOP/CHASER/LEED with auto-PBSCT in untreated mantle cell lymphoma in JCOG0406 study. A continuous pattern of relapse was observed.
4.
Nannya Y, Tobiasson M, Sato S, Bernard E, Ohtake S, Takeda J, et al.
Blood Adv
. 2023 Mar;
7(14):3624-3636.
PMID: 36989067
Azacitidine is a mainstay of therapy for myelodysplastic syndrome (MDS)-related diseases. The purpose of our study is to elucidate the effect of gene mutations on hematological response and overall survival...
5.
Nishi H, Ono M, Ohno S, Yamanaka Z, Sasaki T, Ohyashiki K, et al.
Gynecol Oncol Rep
. 2023 Jan;
45:101138.
PMID: 36714373
Objective: Hypoxia, which occurs during the development of cervical cancer, confers chemotherapy resistance. MicroRNA expression is regulated by hypoxia and is associated with the onset and progression of certain types...
6.
Makishima H, Saiki R, Nannya Y, Korotev S, Gurnari C, Takeda J, et al.
Blood
. 2022 Nov;
141(5):534-549.
PMID: 36322930
Germ line DDX41 variants have been implicated in late-onset myeloid neoplasms (MNs). Despite an increasing number of publications, many important features of DDX41-mutated MNs remain to be elucidated. Here we...
7.
Takeda J, Yoshida K, Nakagawa M, Nannya Y, Yoda A, Saiki R, et al.
Blood Cancer Discov
. 2022 Jul;
3(5):410-427.
PMID: 35839275
Significance: This study reveals the major role of gains, amplifications, and mutations of EPOR and JAK2 in the pathogenesis of pure erythroleukemia. Their frequent response to ruxolitinib in patient-derived xenograft...
8.
Tanaka Y, Okabe S, Ohyashiki K, Gotoh A
Oncol Lett
. 2022 Mar;
23(4):111.
PMID: 35251342
Sphingosine 1-phosphate (S1P) is a bioactive lipid involved in cancer progression through its binding to S1P receptors (S1PRs). However, the association between multiple myeloma (MM) and S1P is unclear. The...
9.
Ohnishi K, Ohmachi K, Ando K, Yamamoto K, Ito T, Tanimoto M, et al.
J Clin Exp Hematop
. 2021 Jul;
61(3):162-167.
PMID: 34193755
The optimal combined chemotherapy regimen with rituximab has yet to be established for elderly patients with advanced-stage indolent B-cell lymphoma (B-NHL). A multicenter study was performed to evaluate the efficacy...
10.
Ochi Y, Yoshida K, Huang Y, Kuo M, Nannya Y, Sasaki K, et al.
Nat Commun
. 2021 May;
12(1):2833.
PMID: 33990592
Blast crisis (BC) predicts dismal outcomes in patients with chronic myeloid leukaemia (CML). Although additional genetic alterations play a central role in BC, the landscape and prognostic impact of these...